NRx Pharmaceuticals

(NASDAQ) NRXP

Current Price$4.35

Market Cap$177.84M

Since IPO (2017)-96%

5 Year-95%

1 Year+41%

1 Month+7%

NRx Pharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 4.24	2026-07-16

NRx Pharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+3.16%	USD 4.11	2026-07-09
1 month	+6.8%	USD 3.97	2026-06-16
3 month	+66.27%	USD 2.55	2026-04-17
Year to date	+56.46%	USD 2.71	2025-12-31
1 year	+40.86%	USD 3.01	2025-07-16
3 year	+7.34%	USD 3.95	2023-07-17
5 year	-95.02%	USD 85.20	2021-07-16
Since inception	-95.58%	USD 96.00	2017-12-04

NRx Pharmaceuticals Financials at a Glance

Market Cap

$177.84M

Revenue (TTM)

$2.29M

Net Income (TTM)

-$24.54M

EPS (TTM)

-$1.28

P/E Ratio

-3.32

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$4.35

Volume

293,166.209

Open

$4.17

Price

$4.35

Volume

293,166.209

Open

$4.17

Previous Close

$4.24

Daily Range

$4.07 - $4.39

52-Week Range

$1.62 - $5.06

Estimated Earnings Date

Aug 17, 2026

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$4.35

Volume

293,166.209

Open

$4.17

Previous Close

$4.24

Daily Range

$4.07 - $4.39

52-Week Range

$1.62 - $5.06

Estimated Earnings Date

Aug 17, 2026

NRXP News

My Top 3 Biotech Stocks for May 2026

Jeff SiegelMay 20, 2026

Medical researchers - GettyImages-1096502340

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NRx Pharmaceuticals

NRx Pharmaceuticals develops medicines for mental health and severe lung conditions. Its treatments help people with depression, suicidal thoughts, and breathing problems. The company also runs clinics offering therapy and medication for patients needing urgent psychiatric care.

What’s in the Medicine Cabinet?

NRX-100 (Ketamine IV): Injectable treatment for severe depression and suicidal thoughts; not yet generating revenue.
KETAFREE: Generic ketamine for depression and pain; targets hospitals and clinics; no revenue yet.
NRX-101: Oral medicine for bipolar depression with suicidal risk; still in development.
ZYESAMI: Investigational drug for COVID-19-related breathing failure; technology transferred to another company.
Clinical Services (HOPE Therapeutics): Psychiatric clinics offering ketamine infusions, therapy, and medication; 100% of 2025 revenue.

Growth Spurts and Strategic Moves

Acquired Dura Medical in September 2025 to expand clinic network.
Invested in Cohen & Associates in 2025 to broaden clinical reach.
Partnered with neurocare AG and EMOBOT in 2025 for device and digital health integration.
Launched new clinical trials for NRX-101 with TMS therapy in late 2025.
Expanded HOPE clinics from zero to five Florida locations in 2025, with more planned.

Why NRx Is a Bit Different

NRx combines drug development with direct patient care through its clinics. It uses real-world patient data to support regulatory filings, a newer approach in the industry. The company holds patents for its drug candidates and treatment methods across several regions.

Five Things You Need to Know

Clinical services made up 100% of 2025 revenue.
2025 revenue was $1.2 million, up from $0 in 2024.
Net loss was $28.6 million in 2025, 14% higher than 2024.
Cash position improved to $7.8 million at end of 2025.
Auditors raised doubt about ongoing operations without new funding.

Bottom Line

NRx has shifted from pure drug development to running psychiatric clinics. The company faces financial challenges but is diversifying its business model.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Jonathan C. Javitt, MD

Website

www.nrxpharma.com

Headquarters

Wilmington, DE 19801, US

NRXP Financials

Key Financial Metrics (TTM)

Gross Margin

37.11%

Operating Margin

-749.67%

Net Income Margin

-1070.26%

Return on Equity

107.73%

Return on Capital

N/A

Return on Assets

-206.17%

Earnings Yield

-30.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$177.84M

Shares Outstanding

41.94M

Volume

293.17K

Avg. Volume

1.29M

Financials (TTM)

Gross Profit

$851.00K

Operating Income

-$17.19M

EBITDA

-$23.33M

Operating Cash Flow

-$14.93M

Capital Expenditure

$0.00

Free Cash Flow

-$14.93M

Cash & ST Invst.

$6.71M

Total Debt

$934.00K

NRx Pharmaceuticals Performance Analysis

NRx Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 1,225,000	N/A

NRx Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	306.2%
Q1	2026-03-31	8.6%

NRx Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -6.04	-91.9%
2023	2023-12-31	USD -3.98	-34.1%
2024	2024-12-31	USD -2.36	-40.7%
2025	2025-12-31	USD -1.34	-43.3%

NRx Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-188.2%
Q3	2025-09-30	72.4%
Q4	2025-12-31	104.2%
Q1	2026-03-31	-491.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$1.07M

N/A

Gross Profit

$272.00K

N/A

Gross Margin

25.47%

N/A

Market Cap

$177.84M

N/A

Market Cap/Employee

$6.13M

N/A

Employees

N/A

Net Income

-$1.43M

+74.1%

EBITDA

-$1.03M

+81.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$6.71M

+21.0%

Total Debt

$934.00K

-88.9%

Accounts Receivable

$181.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$543.00K

N/A

Short Term Debt

$391.00K

-95.3%

Return on Assets

-2.06%

N/A

Return on Invested Capital

1.30%

N/A

Free Cash Flow

-$4.30M

-23.4%

Operating Cash Flow

-$4.30M

-23.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IPSCCentury Therapeutics, Inc.

IPSCCentury Therapeutics, Inc.$2.30+1.55%

KPTIKaryopharm Therapeutics Inc.

KPTIKaryopharm Therapeutics Inc.$9.52+1.53%

EQEquillium, Inc.

EQEquillium, Inc.$2.60+4.00%

CUECue Biopharma, Inc.

CUECue Biopharma, Inc.$30.60+10.11%

SPRBSpruce Biosciences, Inc.

SPRBSpruce Biosciences, Inc.$44.02-0.59%

OTLKOutlook Therapeutics, Inc.

OTLKOutlook Therapeutics, Inc.$1.43-2.40%

COEPCoeptis Therapeutics Holdings, Inc.

COEPCoeptis Therapeutics Holdings, Inc.$10.99-8.57%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.12-0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$69.42-0.02%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$30.23+0.10%

PATHUiPath

PATHUiPath$12.30+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$41.67+0.02%

AAPLApple

AAPLApple$330.32-0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.60-0.04%

Questions About NRXP

What is the current price of NRx Pharmaceuticals?

NRx Pharmaceuticals is trading at $4.35 per share.

What is the 52-week range for NRx Pharmaceuticals?

Over the past 52 weeks, NRx Pharmaceuticals has traded between $1.62 and $5.06.

How much debt does NRx Pharmaceuticals have?

As of the most recent reporting period, NRx Pharmaceuticals reported total debt of $934.00K.

How much cash does NRx Pharmaceuticals have on hand?

NRx Pharmaceuticals reported $6.71M in cash and cash equivalents in its most recent financial results.

What is NRx Pharmaceuticals’s dividend yield?

NRx Pharmaceuticals does not currently have a dividend yield.

NRx Pharmaceuticals

NRx Pharmaceuticals Financials at a Glance

NRXP News

My Top 3 Biotech Stocks for May 2026

Why NRx Pharmaceuticals Stock Soared Today

Why NRX Pharmaceuticals Stock Is Jumping Today

1 Small-Cap Stock With 10X Potential

Why NRx Pharmaceuticals Stock Is Tumbling Today

Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday

Why NRx Pharmaceuticals Stock Is Skyrocketing Today

Why NRx Pharmaceuticals Stock Vaulted Higher Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About NRx Pharmaceuticals

What’s in the Medicine Cabinet?

Growth Spurts and Strategic Moves

Why NRx Is a Bit Different

Five Things You Need to Know

Bottom Line

NRXP Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

NRx Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NRXP

What is the current price of NRx Pharmaceuticals?

What is the 52-week range for NRx Pharmaceuticals?

How much debt does NRx Pharmaceuticals have?

How much cash does NRx Pharmaceuticals have on hand?

What is NRx Pharmaceuticals’s dividend yield?

Premium Investing Services